11:36 AM EST - Knight Therapeutics Inc. : announced today that it has entered into an asset purchase agreement with Orphan Canada Inc. related to the Canadian rights for ATryn® and PHOTOFRIN® (porfimer sodium), two innovative pharmaceutical products approved for sale in multiple jurisdictions. Knight Therapeutics Inc.
shares T.GUD are trading up $0.04 at $6.34.
